Literature DB >> 21780996

Therapeutic Toll-like receptor agonists directly influence mouse and human T cell lymphoma cell viability and cytokine secretion.

Angela Landrigan, Gloria Yiu, Kanika Agarwal, Paul J Utz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21780996      PMCID： PMC3339659          DOI： 10.3109/10428194.2011.606944

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  18 in total

Review 1.  Imiquimod as an antiangiogenic agent.

Authors:  Vincent W Li; William W Li; Katherine E Talcott; Amy W Zhai
Journal:  J Drugs Dermatol       Date:  2005 Nov-Dec       Impact factor: 2.114

2.  Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas.

Authors:  A H Sarris; D Daliani; R Ulmer; M Crow; H E Broxmeyer; W Pugh; M Reiss; F Cabanillas; A B Deisseroth; M Duvic
Journal:  Leuk Lymphoma       Date:  1996-12

Review 3.  Toll-like receptors: lessons to learn from normal and malignant human B cells.

Authors:  David Chiron; Isabelle Bekeredjian-Ding; Catherine Pellat-Deceunynck; Régis Bataille; Gaëtan Jego
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

4.  Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod.

Authors:  David E Spaner; Richard L Miller; Jenny Mena; Larry Grossman; Vicki Sorrenti; Yonghong Shi
Journal:  Leuk Lymphoma       Date:  2005-06

5.  Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.

Authors:  Youn H Kim; Michael Girardi; Madeleine Duvic; Timothy Kuzel; Brian K Link; Lauren Pinter-Brown; Alain H Rook
Journal:  J Am Acad Dermatol       Date:  2010-12       Impact factor: 11.527

6.  Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15.

Authors:  Maria Wysocka; Bernice M Benoit; Sarah Newton; Livio Azzoni; Luis J Montaner; Alain H Rook
Journal:  Blood       Date:  2004-08-24       Impact factor: 22.113

7.  A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.

Authors:  Ingrid López-Lerma; Maria Teresa Estrach
Journal:  J Am Acad Dermatol       Date:  2009-08       Impact factor: 11.527

8.  Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12.

Authors:  Maria Wysocka; Sarah Newton; Bernice M Benoit; Camille Introcaso; Aidan S Hancock; Jihed Chehimi; Stephen K Richardson; Joel M Gelfand; Luis J Montaner; Alain H Rook
Journal:  Clin Lymphoma Myeloma       Date:  2007-09

9.  Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells.

Authors:  Ryan A Wilcox; David A Wada; Steven C Ziesmer; Sherine F Elsawa; Nneka I Comfere; Allan B Dietz; Anne J Novak; Thomas E Witzig; Andrew L Feldman; Mark R Pittelkow; Stephen M Ansell
Journal:  Blood       Date:  2009-08-11       Impact factor: 22.113

Review 10.  Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.

Authors:  Mark W Gramling; Frank C Church
Journal:  Thromb Res       Date:  2010-01-15       Impact factor: 3.944
View more
  1 in total

1.  Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.

Authors:  Laura Gonzalez-Fajardo; Olga Lucía Fernández; Diane McMahon-Pratt; Nancy Gore Saravia
Journal:  PLoS Negl Trop Dis       Date:  2015-05-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.